Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
Leukemia|March 25, 2018
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet studyReinhard Stauder, Ge Yu, Karin A Koinig, et al.
Leukemia & Lymphoma|April 19, 2019
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation<sup>.</sup>Eline M P Cremers, Theo de Witte, Liesbeth de Wreede, et al.
British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.
Haematologica|November 5, 2017
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow TransplantationChristoph Schmid, Liesbeth C de Wreede, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2016
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMTSilke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Blood Advances|January 4, 2018
Haploidentical transplant in patients with myelodysplastic syndromeMarie Robin, Raphael Porcher, Fabio Ciceri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 3, 2018
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry AnalysisMarie Robin, Raphaël Porcher, Annalisa Ruggeri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Leukemia|March 25, 2018
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet studyReinhard Stauder, Ge Yu, Karin A Koinig, et al.
Leukemia & Lymphoma|April 19, 2019
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation<sup>.</sup>Eline M P Cremers, Theo de Witte, Liesbeth de Wreede, et al.
British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.
Haematologica|November 5, 2017
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow TransplantationChristoph Schmid, Liesbeth C de Wreede, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2016
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMTSilke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Blood Advances|January 4, 2018
Haploidentical transplant in patients with myelodysplastic syndromeMarie Robin, Raphael Porcher, Fabio Ciceri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 3, 2018
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry AnalysisMarie Robin, Raphaël Porcher, Annalisa Ruggeri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Pageof 16